OPKO Health is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol "OPK".[2]
OPKO Health is a diversified healthcare company present in more than 30 countries. The company's primary businesses include:
Bioreference Laboratories, the third largest clinical laboratory with a core genetic testing business and a nearly 300 person sales and marketing team
The 4K Test Score, a blood test for prostate cancer accurately used to predict the likelihood of cancer spreading to other body parts within the next 20 years and guide in patient care decisions
Pharmaceutical development such as Rayaldee an FDA approved treatment for secondary hyperparathyroidism (SHIP)
The company also developed Varubi, a chemotherapy inducted nausea medication out-licensed to Tesaro and TerSera Therapeutics
The Chairman and CEO of OPKO is Dr. Phillip Frost, a billionaire biotech entrepreneur who previously held Chairman positions during the early stages and successful sales of Key Pharmaceuticals, Ivax Corporation, and Teva Pharmaceuticals.
In May 2022, OPKO Health announced the acquisition of U.S based Biotechnology firm, ModeX. The Acquisition worth $300 million saw OPKO gain proprietary immunotherapy technology with a focus on infectious diseases and Oncology, to focus on a range of cancers and infectious diseases, with applicability to other therapeutic areas.[3]
Products linesEdit
Diagnostics: Bioreference Laboratory, 4k Test Score, Claros 1 Point of Care Diagnostic Platform Therapeutics: Vitamin D and Phosphate Management Products, Growth Hormone, Hemophilia and Obesity Products, Other Small Molecule and Biological Therapeutics, Vaccines Strategic Investments: ARNO Therapuetics, BioCardia, ChromaDex Corporation, Cocrystal Pharma, MABVAX, Neovasc, Pharmsynthez, RXi Pharmaceuticals, VBI Vaccines, Sevion, Xenetic Biosciences, Zebra Biologic
LitigationEdit
On September 7, 2018, the SEC filed a lawsuit against a number of individuals and entities including Opko Health and the CEO and Chairman, Dr. Phillip Frost. In December 2018, the company and Dr. Frost entered into settlements with the SEC, which, upon approval by the court in January 2019, resolved the claims. Without admitting or denying any of the allegations, the company agreed to an injunction from violations of Section 13(d) of the “Exchange Act”, a strict liability claim, and to pay a $100,000 penalty, which has been paid.[4] On March 8, 2019, the SEC filed an amended complaint, with OPKO paying $100,000 "Without admitting or denying the SEC's allegations."[5]
^"OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases". Yahoo Finance. 9 May 2022. Retrieved 9 May 2022.
^"Array Biopharma Annual Report (Form 10-K)". www.sec.gov. Securities and Exchange Commission. March 1, 2019.
^"SEC Settles with Multiple Defendants in Market Manipulation Case and Amends Complaint as to Thirteen Remaining Defendants". U.S. Securities and Exchange Commission. Mar 22, 2019. Retrieved March 22, 2019.
External linksEdit
opko.com
October 17, 2023
opko, health, this, article, uses, bare, urls, which, uninformative, vulnerable, link, please, consider, converting, them, full, citations, ensure, article, remains, verifiable, maintains, consistent, citation, style, several, templates, tools, available, assi. This article uses bare URLs which are uninformative and vulnerable to link rot Please consider converting them to full citations to ensure the article remains verifiable and maintains a consistent citation style Several templates and tools are available to assist in formatting such as reFill documentation and Citation bot documentation August 2022 Learn how and when to remove this template message This article relies excessively on references to primary sources Please improve this article by adding secondary or tertiary sources Find sources OPKO Health news newspapers books scholar JSTOR March 2018 Learn how and when to remove this template message OPKO Health is a medical test and medication company focused on diagnostics and pharmaceuticals The company is a publicly traded company on NASDAQ and TASE under the symbol OPK 2 OPKO HealthTypePublicTraded asNasdaq OPKRussell 2000 Component TASE OPKIndustryMedical Appliances amp EquipmentFounded1991 HeadquartersMiami FloridaProductsMedical ProductsNumber of employees6 096 1 Websitewww wbr opko wbr com Contents 1 History 2 Products lines 3 Litigation 4 References 5 External linksHistory EditOPKO Health is a diversified healthcare company present in more than 30 countries The company s primary businesses include Bioreference Laboratories the third largest clinical laboratory with a core genetic testing business and a nearly 300 person sales and marketing team The 4K Test Score a blood test for prostate cancer accurately used to predict the likelihood of cancer spreading to other body parts within the next 20 years and guide in patient care decisions Pharmaceutical development such as Rayaldee an FDA approved treatment for secondary hyperparathyroidism SHIP The company also developed Varubi a chemotherapy inducted nausea medication out licensed to Tesaro and TerSera TherapeuticsThe Chairman and CEO of OPKO is Dr Phillip Frost a billionaire biotech entrepreneur who previously held Chairman positions during the early stages and successful sales of Key Pharmaceuticals Ivax Corporation and Teva Pharmaceuticals In May 2022 OPKO Health announced the acquisition of U S based Biotechnology firm ModeX The Acquisition worth 300 million saw OPKO gain proprietary immunotherapy technology with a focus on infectious diseases and Oncology to focus on a range of cancers and infectious diseases with applicability to other therapeutic areas 3 Products lines EditDiagnostics Bioreference Laboratory 4k Test Score Claros 1 Point of Care Diagnostic Platform Therapeutics Vitamin D and Phosphate Management Products Growth Hormone Hemophilia and Obesity Products Other Small Molecule and Biological Therapeutics Vaccines Strategic Investments ARNO Therapuetics BioCardia ChromaDex Corporation Cocrystal Pharma MABVAX Neovasc Pharmsynthez RXi Pharmaceuticals VBI Vaccines Sevion Xenetic Biosciences Zebra BiologicLitigation EditOn September 7 2018 the SEC filed a lawsuit against a number of individuals and entities including Opko Health and the CEO and Chairman Dr Phillip Frost In December 2018 the company and Dr Frost entered into settlements with the SEC which upon approval by the court in January 2019 resolved the claims Without admitting or denying any of the allegations the company agreed to an injunction from violations of Section 13 d of the Exchange Act a strict liability claim and to pay a 100 000 penalty which has been paid 4 On March 8 2019 the SEC filed an amended complaint with OPKO paying 100 000 Without admitting or denying the SEC s allegations 5 References Edit https www owler com company opko bare URL Business Summary Retrieved Dec 22 2013 OPKO Health Acquires ModeX Therapeutics Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases Yahoo Finance 9 May 2022 Retrieved 9 May 2022 Array Biopharma Annual Report Form 10 K www sec gov Securities and Exchange Commission March 1 2019 SEC Settles with Multiple Defendants in Market Manipulation Case and Amends Complaint as to Thirteen Remaining Defendants U S Securities and Exchange Commission Mar 22 2019 Retrieved March 22 2019 External links Editopko wbr com Retrieved from https en wikipedia org w index php title OPKO Health amp oldid 1177306685, wikipedia, wiki, book, books, library,
